Results 221 to 230 of about 5,039,430 (289)
Some of the next articles are maybe not open access.
Thrombosis with Epsilon Aminocaproic Acid Therapy
American Journal of Clinical Pathology, 1971A patient with postoperative bleeding was treated with epsilon aminocaproic acid (EACA). Subsequent coagulation studies supported the diagnosis of intravascular coagulation and the patient subsequently developed renal failure due to glomerular thromboses.
Harvey R. Gralnick, Philip Greipp
openaire +3 more sources
Aminocaproic Acid in the Treatment of Traumatic Hyphema
American Journal of Ophthalmology, 1976Of 59 patients with traumatic hyphema studied prospectively, 32 received aminocaproic acid, an antifibrinolytic agent, to prevent secondary hemorrhage. The remaining 27 patients received placebo in an identical manner. Of the aminocaproic acid-treated patients, only one (3%) rebled, while nine patients (33%) receiving placebo suffered secondary ...
Earl R. Crouch, Marcel Frenkel
openaire +3 more sources
Effect of -Aminocaproic Acid on Postvitrectomy Hemorrhage
Archives of Ophthalmology, 1985We performed a prospective study involving 96 patients undergoing vitrectomy for proliferative diabetic retinopathy to determine the effect of epsilon-aminocaproic acid on the occurrence of postoperative intraocular hemorrhage. epsilon-Aminocaproic acid significantly reduced postoperative vitreous hemorrhage during the immediate postoperative period ...
S. De Bustros +3 more
openaire +3 more sources
Effect of probenecid on the kinetics of epsilon-aminocaproic acid
Clinical Pharmacology and Therapeutics, 1980Healthy male subjects received, 1 wk apart, single oral doses of epsilon-aminocaproic acid (EACA) 100 mg/kg alone, EACA within probenecid (0.5 gm), or EACA 2 hr after 2.0 gm probenecid. Probenecid (2.0 gm) reduced the 8-hr urinary clearance and recovery of EACA by 50% without affecting plasma kinetics.
Kerry L Katlic +3 more
openaire +3 more sources
Myoglobinuria Following Aminocaproic Acid Administration
JAMA: The Journal of the American Medical Association, 1976To the Editor.— e-Aminocaproic acid (EACA), a specific inhibitor of plasminogen activation, was originally used in low dosage as an antifibrinolytic agent and is now being employed in higher doses in the treatment of hereditary angioneurotic edema. We have recently encountered a 24-year-old woman receiving high doses of EACA who had rhabdomyolysis and
Robert A. Rizza +2 more
openaire +2 more sources
Epsilon-Aminocaproic acid therapy in ulcerative colitis
The American Journal of Digestive Diseases, 1973A double-blind cross-over trial of the effect of Epsilon-Aminocaproic acid (EACA) versus placebo on gastrointestinal blood loss in 13 patients with proctocolitis showed no statistically significant reduction in blood loss recorded by the disappearance rate, as detected by whole-body monitoring of parenterally administered59Fe.
K. Boddy +5 more
openaire +3 more sources
Epsilon Aminocaproic Acid — A Dangerous Weapon
New England Journal of Medicine, 1969Of the body's defenses against injury, the proteolytic activity of plasmin, an enzyme that can evolve in plasma from an inert precursor, plasminogen, is most intriguing. Clinical attention has been centered upon the digestion of fibrin by plasmin, but this enzyme also digests other clotting factors, converts the first component of complement to its ...
openaire +2 more sources
AMINOCAPROIC ACID, AN INHIBITOR OF FIBRINOLYSIS
The American Journal of the Medical Sciences, 1965Harry Gold +2 more
openaire +3 more sources